Sodium-Glucose Co-Transport Inhibitors: Progress and Therapeutic Potential in Type 2 Diabetes Mellitus

ISSN： 0012-6667

Source： Drugs, Vol.70, Iss.4, 2010-03, pp. : 377-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

By Boyle Luke D Wilding John PH

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 375-391

Informa Healthcare

Access to resources Recommend Favorite

Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

By Lamos Elizabeth M

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 6, 2013-06 ,pp. : 763-775

Informa Healthcare

Access to resources Recommend Favorite

Miglitol: A Review of its Therapeutic Potential in Type 2 Diabetes Mellitus

By Scott L.J. Spencer C.M.

Drugs, Vol. 59, Iss. 3, 2000-03 ,pp. : 521-549

Adis International

Access to resources Recommend Favorite

Sodium-Glucose Co-Transporter 2 Inhibition in Diabetes Treatment: Current Evidence and Future Perspectives

Current Pharmaceutical Design, Vol. 20, Iss. 22, 2014-05 ,pp. : 3647-3656

Bentham Science Publishers

Access to resources Recommend Favorite

Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to ‘Sweet Pee’

Current Pharmaceutical Design, Vol. 16, Iss. 34, 2010-11 ,pp. : 3830-3838

Bentham Science Publishers

Access to resources Recommend Favorite